EBV vaccine study for healthy adults 18 to 30
Part of Infections clinical trials.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 30 years old.
- You are generally healthy, based on your medical history and a physical exam.
- If you could become pregnant, you are not pregnant and are not breastfeeding.
- You have not received an experimental EBV vaccine before.
- You have not had heart inflammation (myocarditis or pericarditis) in the past.
- You are not taking high-dose steroids (more than 10 mg of prednisone per day) or strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA vaccine designed to protect against the Epstein-Barr virus, which is a common virus that can cause illnesses like mono. It is for healthy young adults to see if the vaccine is safe and triggers a good immune response.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This study tests a new mRNA vaccine that helps your immune system fight cancer cells linked to the Epstein-Barr virus. It may be an option for people with advanced EBV-positive cancers that have not responded to standard treatments.
Hear when a new Epstein-Barr Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.